As previously disclosed, on June 2, 2021, Constellation Pharmaceuticals, Inc. (Constellation), entered into an Agreement and Plan of Merger with MorphoSys AG (Aktiengesellschaft) (MorphoSys), and MorphoSys Development Inc., an indirect wholly owned subsidiary of MorphoSys (Purchaser). In accordance with the Merger Agreement, at the effective time of the Merger, Jigar Raythatha resigned as Chief Executive Officer of Constellation.